Latest On Edesa Biotech, Inc (EDSA):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-11 19:16 EST | News | Edesa Biotech GAAP EPS of -$0.12 beats by $0.05 | N/A |  |
| 2023-02-10 13:00 EST | News | Edesa Biotech GAAP EPS of -$0.13 beats by $0.06 | N/A | |
| 2023-02-01 16:16 EST | News | Edesa gets Health Canada nod to start mid-stage study for vitiligo drug | N/A | |
| 2023-01-17 19:41 EST | News | Edesa stock slumps 30% amid skin rash drug's mixed phase 2b trial results | N/A | |
| 2022-12-22 14:23 EST | News | RENN, LX and THMO among premarket gainers | N/A | |
About Edesa Biotech, Inc (EDSA):
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with N read more...ovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
General
- Name Edesa Biotech, Inc
- Symbol EDSA
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 12
- Last Split Factor1:6
- Last Split Date2019-06-10
- Fiscal Year EndSeptember
- IPO Date2015-11-05
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.edesabiotech.com
Valuation
- Price/Sales (Trailing 12 Mt.) 239.03
- Price/Book (Most Recent Quarter) 9.49
- Enterprise Value Revenue 310.87
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.07
- Next Year EPS Estimate -$1.84
- Next Quarter EPS Estimate -$0.27
- Operating Margin -3579%
- Return on Assets -64%
- Return on Equity -117%
- Revenue 221001
- Earnings Per Share -$5.79
- Revenue Per Share $0.02
- Gross Profit 311200
- Quarterly Earnings Growth -99.9%
Highlights
- Market Capitalization 74.85 million
- EBITDA -2623543
- Analyst Target Price $17
- Book Value Per Share $0.56
Share Statistics
- Shares Outstanding 13.18 million
- Shares Float 6.54 million
- % Held by Insiders 3865%
- % Held by Institutions 21.14%
- Shares Short 268810
- Shares Short Prior Month 89004
- Short Ratio 0.2
- Short % of Float 4%
- Short % of Shares Outstanding 2%
Technicals
- 52 Week High $10.15
- 52 Week Low $1.7
- 50 Day Moving Average 6.18
- 200 Day Moving Average 6.18
Dividends
- Dividend Date 2019-06-10
- ExDividend Date N/A
- Dividend Yield 0%
Edesa Biotech, Inc (EDSA) Dividend Calendar:
EDSA's last dividend payment was made to shareholders on June 10, 2019.
Edesa Biotech, Inc (EDSA) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Edesa Biotech, Inc (EDSA) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Apr 30 2020 | Mar 31 2020 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | 1.14 million | 502814 |
| Income Before Tax | N/A | N/A | N/A | -1.77 million | -1.49 million |
| Selling General Administrative | N/A | N/A | N/A | 733079 | 1.11 million |
| Gross Profit | N/A | N/A | N/A | 108513 | 100479 |
| Ebit | N/A | N/A | N/A | -1.74 million | -1.51 million |
| Operating Income | N/A | N/A | N/A | -1.77 million | -1.52 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | 109985 | 110516 |
| Cost of Revenue | N/A | N/A | N/A | 1472 | 10037 |
| Total Other Income Expense Net | N/A | N/A | N/A | -1128 | 7845 |
| Net Income From Continuing Operations | N/A | N/A | N/A | -1.77 million | -1.49 million |
| Net Income Applicable to Common Shares | -2.64 million | -2.01 million | -1.77 million | -1.77 million | N/A |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Apr 30 2020 | Mar 31 2020 | Jan 31 2020 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | -26827 | 519652 | 519652 |
| Change to Liabilities | 525215 | N/A | 397882 | N/A | -99493 |
| Total Cash Flow from Investing Activities | 3541 | N/A | -26827 | N/A | 519652 |
| Net Borrowings | 88 | N/A | 29660 | N/A | 29660 |
| Total Cash Flow from Financial Activities | N/A | -27494 | -27494 | 3.85 million | 3.85 million |
| Change to Operating Activities | -269401 | N/A | -123123 | N/A | -1365 |
| Change in Cash | N/A | -1.35 million | -1.35 million | 3.16 million | 3.16 million |
| Total Cash from Operating Activities | -1.67 million | -1.35 million | -1.35 million | -1.17 million | -1.17 million |
| Depreciation | N/A | N/A | 23489 | 2651 | 2651 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | -7021 | N/A | -57154 | N/A | -468699 |
| Change to Net Income | 85957 | N/A | 85056 | N/A | 399132 |
| Capital Expenditures | N/A | 29483 | 29483 | N/A | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Apr 30 2020 | Mar 31 2020 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 701681 |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 6.93 million |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Assets | N/A | N/A | N/A | N/A | 7.63 million |
| Common Stock | 21.7 million | 18.5 million | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | 14.78 million | N/A |
| Retained Earnings | -15.78 million | -13.13 million | N/A | -11.1 million | -9.32 million |
| Other Liabilities | 47082 | 29928 | N/A | 29320 | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A |
| Cash | N/A | N/A | 5.64 million | N/A | 6.99 million |
| Total Current Liabilities | 906327 | 1.53 million | N/A | N/A | 578938 |
| Other Stockholder Equity | -183777 | -287204 | N/A | -294896 | N/A |
| Property, Plant & Equipment | 165201 | 174821 | N/A | 193118 | N/A |
| Total Current Assets | 7.67 million | 8.1 million | N/A | N/A | 7.43 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 5.43 million | 4.15 million | N/A | 2.83 million | N/A |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 831450 | 1.46 million | N/A | N/A | N/A |
Edesa Biotech, Inc (EDSA) Chart:
Edesa Biotech, Inc (EDSA) News:
Below you will find a list of latest news for Edesa Biotech, Inc (EDSA) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Edesa Biotech, Inc (EDSA) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest EDSA Trades:
Edesa Biotech, Inc (EDSA) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-11-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-28 | 8-K (Current report) | |
| 2020-09-28 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-09-28 | 8-K (Current report) | |
| 2020-09-18 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-09-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-12 | 8-K (Current report) | |
| 2020-08-12 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
Edesa Biotech, Inc (EDSA) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Edesa Biotech, Inc (EDSA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 3865%
Institutional Ownership: 2114%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-05-27 | Michael J Brooks | President | Buy | 1,500.00 | 3.00 | 4,498.50 | 3,327.00 | |
| 2020-05-27 | Michael J Brooks | President | Buy | 1,000.00 | 3.00 | 3,000.00 | 4,327.00 | |
| 2020-05-26 | Pardeep Nijhawan | Chief Executive Officer | Buy | 3,000.00 | 2.98 | 8,939.10 | 2,124,024.00 | |
| 2020-03-17 | Pardeep Nijhawan | Chief Executive Officer | Buy | 1,000.00 | 1.89 | 1,889.90 | 2,117,024.00 | |
| 2020-03-17 | Pardeep Nijhawan | Chief Executive Officer | Buy | 1,000.00 | 1.86 | 1,859.90 | 2,118,024.00 | |
| 2020-03-17 | Pardeep Nijhawan | Chief Executive Officer | Buy | 1,000.00 | 1.90 | 1,897.80 | 2,119,024.00 | |
| 2020-03-17 | Pardeep Nijhawan | Chief Executive Officer | Buy | 1,000.00 | 1.83 | 1,828.00 | 2,120,024.00 | |
| 2020-03-17 | Pardeep Nijhawan | Chief Executive Officer | Buy | 1,000.00 | 1.90 | 1,897.50 | 2,121,024.00 | |
| 2020-01-08 | FRANK R. OAKES | Director | Buy | 1,218.00 | 4.11 | 5,005.98 | 1,218.00 | |
| 2020-01-08 | KATHI NIFFENEGGER | Chief Financial Officer | Buy | 1,218.00 | 4.11 | 5,005.98 | 1,218.00 | |
| 2020-01-08 | der Velden Peter van | Director | Buy | 11,903.00 | 3.20 | 38,089.60 | 169,502.00 | |
| 2020-01-08 | Michael J Brooks | President | Buy | 1,827.00 | 4.11 | 7,508.97 | 1,827.00 | |
| 2020-01-08 | der Velden Peter van | Director | Buy | 128,722.00 | 3.20 | 411,910.40 | 1,833,066.00 | |
| 2020-01-08 | Pardeep Nijhawan | Chief Executive Officer | Buy | 9,255.00 | 4.11 | 38,038.05 | 2,116,024.00 | |
| 2020-01-08 | Carlo Sistilli | Director | Buy | 2,436.00 | 4.11 | 10,011.96 | 2,436.00 | |
| 2020-01-08 | Paul William Pay | Director | Buy | 2,436.00 | 4.11 | 10,011.96 | 2,436.00 | |
| 2020-01-08 | LORIN K JOHNSON | Director | Buy | 8,524.00 | 4.11 | 35,033.64 | 8,524.00 | |
| 2019-09-11 | FRANK R. OAKES | Director | Sell | 1,809.00 | 5.72 | 10,345.13 | 6,165.00 | |
| 2019-07-26 | Sean Arthur MacDonald | Director | Buy | 786.00 | 14,369.00 | | ||
| 2019-07-26 | der Velden Peter van | Director | Buy | 8,600.00 | 157,599.00 | |